A total of 24 patients under 75 years old with stage II breast cancer undertook induction chemotherapy (EC and/or taxane) prior to KORTUC II treatment, and 58 patients with estrogen receptor-positive tumors were also started on hormone therapy following KORTUC II treatment. Here, ESR1 is linked to breast carcinoma.